Clonal evolution of resistance to sequential ALK inhibitor therapy.

Slides:

Advertisements

Similar presentations

A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation Fumio Imamura, Takako Inoue, Madoka Kimura,

Advertisements

Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports Daniel K. Ebner, BS, Tadashi Kamada, MD, PhD,

Acquired Resistance to Crizotinib from a Mutation in CD74-ROS1 Mark M

Fig. 10. MIP (A, C) and axial non contrast fused 18F-FDG PET/CT (B) in 20-year-old man with ALK positive anaplastic large cell lymphoma. A. Patient had.

Fig FDG PET-CT and diagnostic contrast-enhanced chest CT in patient with angioimmunoblastic T-cell lymphoma. MIP image (A) demonstrates intense 18FDG.

Christopher S. Lathan, M. D. , M. S. , M. P. H

Dose-escalation patient response.

The New Taxonomy of Metastatic NSCLC and Physician Treatment Based on Pathologic and Molecular Characteristics The New Taxonomy of Metastatic Non-Small.

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors Alexa B. Schrock,

Summary of genetic alterations in resistant biopsies among patients progressing on ceritinib or alectinib. Summary of genetic alterations in resistant.

Figure 3 Monitoring clonal evolution using liquid biopsies

Monitoring EGFR mutation status in Non-small cell lung cancer (NSCLC) patients using circulating Tumour DNA (ctDNA). Matthew Smith Molecular Pathology.

Recent Advances in Targeting ROS1 in Lung Cancer

Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance.

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.

Clonal evolution in Ewing sarcoma.

Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH /RO )

Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR Eamon M. Berge, MD, Dara L. Aisner, MD, PhD, Robert C. Doebele,

Moving Care Forward in Advanced NSCLC

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

Caught in transformation

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Osteoblastic Response in Patients with Non-small Cell Lung Cancer with Activating EGFR Mutations and Bone Metastases during Treatment with EGFR Kinase.

Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors Hsin-Yi Wang, MD Journal of Thoracic.

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping

Clinical responses in patients.

Metabolic response by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT). a) FDG PET/CT for patient 2 at baseline.

Recent Advances in Targeting ROS1 in Lung Cancer

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,

Identification of a Novel HIP1-ALK Fusion Variant in Non–Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged.

Matthew Reichert, MD, Eric S. Bensadoun, MD

Proposed spiral model for prostate cancer progression.

Figure 1 Evolution of MRI findings during interleukin (IL)–7 therapy

Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC Francesco Gelsomino, MD, Valentina.

Multimodality imaging of aortic stenosis.

High-level clonal amplification of FGFR2 predicts for sensitivity to FGFR inhibitor. High-level clonal amplification of FGFR2 predicts for sensitivity.

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

A and B, Axial and coronal high-resolution CT images of the larynx in a 73-year-old patient with papillary thyroid cancer and left vocal cord paralysis.

ALK resistance mutations predict for sensitivity to lorlatinib in patient-derived cell line models of acquired resistance to ceritinib. ALK resistance.

Fig. 1 Molecular imaging of EGFR-activating mutation status for stratification of patients. Molecular imaging of EGFR-activating mutation status for stratification.

CT (left of images) showing calcified areas and PET (right of images) scans showing increased FDG-PET metabolic activity in the mediastinal mass (A) and.

Fig year-old woman with newly diagnosed inflammatory breast cancer. A-C. Axial fused PET-CT images of supraclavicular region, upper and mid chest.

Temporal analysis of clonal evolution in typical FL and matched TFL samples. Temporal analysis of clonal evolution in typical FL and matched TFL samples.

A and B, CT images on a patient status post total thyroidectomy for thyroid cancer show a small enhancing lesion near the right tracheoesophageal groove.

The treatment history and genomic landscape of a metastatic carcinoma with an extreme outlier response to combination therapy. The treatment history and.

Plasma and tissue EGFR allele analyses.

Delineation of the clinical course and evolution of BRAF mutation status in the seven patients with BRAF V600E mutation. Delineation of the clinical course.

Serial chest CT scans of 33-year-old male with lung adenocarcinoma harboring EGFR-KDD documenting response to afatinib and subsequent acquired resistance.

Antitumor activity. Antitumor activity. A, maximum change in target lesion size from baseline assessed according to RECIST 1.0 (n = 26). Six patients had.

Noninvasive detection of acquired MET amplification as a mechanism of afatinib/trastuzumab resistance using cfDNA. Noninvasive detection of acquired MET.

Molecular heterogeneity can drive mixed response and treatment failure in EGC. A, PET images from Patient #4 obtained before treatment and upon disease.

MEK1F53L mutation drives clinical acquired resistance to combined RAF/MEK inhibition. MEK1F53L mutation drives clinical acquired resistance to combined.

Combined inhibition of coamplified RTKs is required for response.

Frequent coamplification of RTKs in MET-amplified EGC

A and B, two blocks from the original specimen used for TMA demonstrated areas with varying patterns of ALK rearrangement and KRAS mutation status. A and.

No single ALK mutations confer high-level resistance to lorlatinib.

Tracking resistance to TRKA inhibition in ctDNA of a patient with colorectal cancer. Tracking resistance to TRKA inhibition in ctDNA of a patient with.

Serial CT scan images from patient with a partial response.

Crizotinib-resistant NPM-ALK mutants retain sensitivity to ganetespib.

SD-101 and low-dose radiation induces responses in patients with indolent lymphoma. SD-101 and low-dose radiation induces responses in patients with indolent.

Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure Joel P. Womack,

Concordance between liquid versus tissue biopsies.

An isogenic cell line screen reveals genomic drivers of drug response.

A, Changes in BRAFV600E cfDNA allele fraction from baseline after one dose of treatment for 12 patients with serial samples available, classified according.

THZ1 in combination with targeted therapy enhances cell death and hinders the establishment of drug-resistant colonies in diverse oncogene-addicted cellular.

SCLC PDX models recapitulate patient responses to an experimental therapy. SCLC PDX models recapitulate patient responses to an experimental therapy. A,

Single-site disease progression after 9 months of response to therapy in the right hemipelvis visualized by diffusion-weighted whole-body MRI. Top, fusion.

Response and resistance to savolitinib and osimertinib in a patient with EGFR-mutant NSCLC harboring MET amplification. Response and resistance to savolitinib.

Presentation transcript:

Clonal evolution of resistance to sequential ALK inhibitor therapy. Clonal evolution of resistance to sequential ALK inhibitor therapy. A, the treatment course of patient MGH086. Of note, the patient received several lines of therapy, including the EGFR inhibitor erlotinib, before identification of an ALK rearrangement. The points at which the patient underwent biopsies are indicated in red. B, fused positron emission tomography (PET)–computed tomography (CT) images demonstrate a hypermetabolic, left axillary lymph node (white arrow) that developed at the time of disease progression on crizotinib. WES revealed an ALKE1210K mutation [cancer cell fraction (CCF) 0.82]. This axillary lymph node initially responded to brigatinib but recurred after 12 months. WES of this brigatinib-resistant lesion (MGH086-0) demonstrated continued presence of the ALKE1210K mutation and a new ALKS1206C mutation. The patient remained on brigatinib. After an additional 9 months on brigatinib, he developed another recurrence in the left axilla (slightly more inferior than the prior lesion). Repeat WES (MGH086-1) revealed a new compound ALKE1210K+D1203N mutation. C, a model of clonal evolution of resistance to sequential ALK inhibitor therapy in patient MGH086. Using WES, we determined that a founder ALKE1210K subclone was not present in a pre-crizotinib biopsy but later developed on crizotinib. When the patient was switched to brigatinib, the ALKE1210K subclone expanded and ultimately acquired a new ALK mutation, S1206C. Surgical excision of this site of progression may have depleted the compound mutant (ALKE1210K+S1206C), but microscopic parental E1210K clones may have persisted, ultimately acquiring ALKD1203N in combination with ALKE1210K. Justin F. Gainor et al. Cancer Discov 2016;6:1118-1133 ©2016 by American Association for Cancer Research